News >

Nivolumab/Ipilimumab Plus Chemo Improves OS in Frontline NSCLC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Oct 22, 2019

Fouad Namouni, MD, head, Oncology Development, Bristol-Myers Squibb

Fouad Namouni, MD

The first-line combination of nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) given concomitantly with 2 cycles of chemotherapy showed superior overall survival (OS) compared with up to 4 cycles of chemotherapy alone followed by optional maintenance treatment for patients with advanced non–small cell lung cancer (NSCLC), meeting the primary endpoint of the phase III CheckMate-9LA trial (NCT03215706).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication